More than 3 million Medicare patients could be eligible for coverage of Wegovy to reduce heart disease risks, study says
Publishing timestamp: 2024-04-24 05:00:01
Summary
More than 3 million people with Medicare could be eligible for coverage of Novo Nordisk's Wegovy, a weight loss drug now approved in the U.S. for heart health. However, some beneficiaries may still face out-of-pocket costs and certain Medicare prescription drug plans may not cover Wegovy until 2025. Medicare's budget could also be strained as more plans cover the costs of Wegovy.
Sentiment: NEUTRAL
Keywords: pharmaceuticals, business news, novo nordisk a/s, business, breaking news, biotechnology, health care industry, social issues, biotech and pharmaceuticals,